conjugated estrogens/progestin (MPA)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Replacement Therapy
Conditions
Estrogen Replacement Therapy
Trial Timeline
Nov 1, 2006 → Feb 1, 2007
NCT ID
NCT00401219About conjugated estrogens/progestin (MPA)
conjugated estrogens/progestin (MPA) is a phase 1 stage product being developed by Pfizer for Estrogen Replacement Therapy. The current trial status is completed. This product is registered under clinical trial identifier NCT00401219. Target conditions include Estrogen Replacement Therapy.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Replacement Therapy were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00401219 | Phase 1 | Completed |
Competing Products
20 competing products in Estrogen Replacement Therapy